Stefan Kaluz, PhD

    Instructor

    Emory University Department of Neurosurgery

    Instructor

    Laboratory of Molecular Neuro-Oncology

    Education

    • BS, MS, Comenius University, Bratislava, Czechoslovakia
    • PhD, Comenius University, Bratislava, Czechoslovakia

    Biography

    Honors

    • State Final Examination with Disctinction, 1982
    • University of Oxford Soros Fellowship, 1990
    • University of Oxford EMBO Fellowship, 1992

    Society Memberships

    • Acta Virologica Editorial Board

    Research

    Dr. Kaluz is a highly motivated researcher with extensive expertise in the area of hypoxia and deep interest in cancer research in general.

    Publications

    • Fan, J., Shan, C., Kang, H.B., Elf, S., Xie, J., Tucker, M., Gu, T.L., Aguiar, M., Lonning, S., Chen, H., Mohammadi, M., Britton, L.M., Garcia, B.A., Alečković, M., Kang, Y., Kaluz, S., Devi, N., Van Meir, E.G., Hitosugi, T., Seo, J.H., Lonial, S., Gaddh, M., Arellano, M., Khoury, H.J., Khuri, F.R., Boggon, T.J., Kang, S., Chen, J. (2014). Tyr-phosphorylation of PDP1 toggles recruitment between ACAT1 and SIRT3 to regulate pyruvate dehydrogenase complex. Mol. Cell, 53, 534–548.
    • Yin, S., Kaluz, S., Devi, N.S., Jabbar, A.A.,  de Noronha, R.G., Mun, J., Zhang, Z., Boreddy, P.R., Wang, W., Wang, Z., Abbruscato, T., Chen, Z., Olson, J.J., Zhang, R., Goodman, M.M., Nicolaou, K.C., Van Meir, E.G. (2012). Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1α interaction with co-factors p300/CBP. Clin Cancer Res, 18, 6623-6633.
    • Shi, Q., Yin, S., Kaluz, S., Ni, N., Devi, N.S., Mun, J., Wang, D., Damera, K., Chen, W., Burroughs, S., Reid Mooring, S., Goodman, M.M., Van Meir, E.G., Wang, B., Snyder, J.P. (2012). Binding Model for the Interaction of Anticancer Arylsulfonamides with the p300 Transcription Cofactor. ACS Med. Chem. Lett. 3, 620−625.
    • Cork, S., Kaur, B., Devi, N.S., Cooper, L., Saltz, J., Kaluz, S., Van Meir, E.G. (2012). A furin/MMP-14 proteolytic cascade generates Vasculostatin-40 from extracellular BAI1. Oncogene, 31, 5144-5152.
    • Reid Mooring, S., Jin, H, Devi, N.S., Jabbar, A.A., Kaluz, S., Liu, Y., Van Meir, E.G., Wang, B. (2011). Design and Synthesis of Novel Small-Molecule Inhibitors of the Hypoxia Inducible Factor Pathway. J. Med. Chem. 54, 8471−8489.
    • Tan, C., de Noronha, R.G., Devi, N.S., Jabbar, A.A., Kaluz, S., Liu, Y., Reid Mooring, S., Nicolaou, K.C., Wang, B., Van Meir, E.G. (2011). Sulfonamides as a new scaffold for hypoxia inducible factor pathway inhibitors. Bioorg. Med. Chem. Lett., 21, 5528-5532.
    • Cao, J.N., Shafee, N., Vickery, L., Kaluz, S., Ru, N., Stanbridge, E.J. (2010). Mitogen-activated protein/extracellular signal-regulated kinase kinase 1 act/tubulin interaction is an important determinant of mitotic stability in cultured HT1080 human fibrosarcoma cells. Cancer Res., 70, 6004-6014.
    • Shafee, N., Kaluz, S., Ru, N., Stanbridge, E.J. (2009). PI3K/Akt activity has variable cell-specific effects on expression of HIF target genes, CA9 and VEGF, in human cancer cell lines. Cancer Lett., 282, 109-115.
    • Kaluz, S. (corresponding author), Kaluzová, M. and Stanbridge, E.J. (2008). Rational design of minimal hypoxia-inducible enhancers. Biochem. Biophys. Res. Commun., 370, 613-618.
    • Kaluz, S. (corresponding author) (*), Kaluzová, M (*). and Stanbridge, E.J. (2006). Proteasomal inhibition attenuates transcriptional activity of hypoxia-inducible factor 1 (HIF-1) via specific effect on the HIF-1alpha C-terminal activation domain. Mol. Cell. Biol., 26, 5895-5907.